Our SCiP™ device has received FDA Breakthrough Device Designation for the treatment of movement disorders in Cerebral Palsy. We anticipate a multicenter pivotal trial to commence in H1 2024.
Our SCONE™ device has received FDA Breakthrough Device Designation for the treatment of neurogenic bladder due to spinal cord injury, Multiple Sclerosis, and stroke. Our pivotal clinical trial is currently ongoing at multiple centers across the US and globally.
Our products address a massive unmet clinical need, with an estimated > $15B combined marketsize. We are quick to market and have first-mover advantage.
Our world-leading team can execute swiftly and effectively, bringing ideas from the bench to market with minimal delays: we have 10 FTEs with decades of cumulative MedTech experience, dozens of products brought to market, deep IP knowledge and significant clinical evidence.
To date we’ve raised
We’d love to talk to you. Email firstname.lastname@example.org